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The development of novel treatment against tuberculosis is a priority global health
challenge. Antimicrobial proteins and peptides offer a multifaceted mechanism
suitable to fight bacterial resistance. Within the RNaseA superfamily there is a group
of highly cationic proteins secreted by innate immune cells with anti-infective and
immune-regulatory properties. In this work, we have tested the human canonical
members of the RNase family using a spot-culture growth inhibition assay based
mycobacteria-infected macrophage model for evaluating their anti-tubercular properties.
Out of the seven tested recombinant human RNases, we have identified two
members, RNase3 and RNase6, which were highly effective against Mycobacterium
aurum extra- and intracellularly and induced an autophagy process. We observed
the proteins internalization within macrophages and their capacity to eradicate the
intracellular mycobacterial infection at a low micro-molar range. Contribution of the
enzymatic activity was discarded by site-directed mutagenesis at the RNase catalytic
site. The protein induction of autophagy was analyzed by RT-qPCR, western blot,
immunofluorescence, and electron microscopy. Specific blockage of auto-phagosome
formation and maturation reduced the protein’s ability to eradicate the infection.
In addition, we found that the M. aurum infection of human THP1 macrophages
modulates the expression of endogenous RNase3 and RNase6, suggesting a function
in vivo. Overall, our data anticipate a biological role for human antimicrobial RNases
in host response to mycobacterial infections and set the basis for the design of novel
anti-tubercular drugs.
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INTRODUCTION
Tuberculosis (TB) is an ancient life-threatening infectious disease currently rated among the top ten
causes of death worldwide. According to theWorld Health Organization (WHO), TB is responsible
for about 1.6 million TB deaths and 10million (5.8 millionmen, 3.2 million women, and 1.0 million
children) new cases have been detected in 2017 and more than a third of the world population is
hostingMycobacterium tuberculosis, the causative pathogen of TB, in its latent form (1, 2). In recent
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years, we have seen a general decline in the TB incidence rate as
well as in the absolute number of registered cases of tuberculosis.
Nonetheless, the emergence of a growing number of new cases
of multi-drug resistant TB (MDR-TB) and even more alarming
extensively drug-resistant TB (XDR-TB) cases have placed the
eradication of TB as one of the major global challenges to
overcome in the twenty-first century. Furthermore, TB prognosis
is significantly aggravated during human immunodeficiency
virus (HIV) co-infection. A complex cellular machinery
is activated during the host immune response against M.
tuberculosis (Mtb) bacilli; unfortunately, their underlying
mechanisms remain poorly understood. Hence, enlargement
of novel and effective therapies to battle mycobacteria are
urgently required (3, 4). Mtb is an intracellular pathogen able to
survive indefinitely under unfavorable conditions inside primary
host immune cells, preferably residing in human alveolar
macrophages (5, 6). Several studies have recently shown that
features such as its high infectivity, slow growth, and complex
cell-wall structure, make M. tuberculosis a major challenge
to be faced, since the specific mechanisms that reinforce the
high virulence of Mtb remain largely unknown (4, 7). Despite
the antimicrobial activity of macrophages, Mtb has been able
to establish a series of strategies to handle the host immune
machinery, interfere with, and arrest the phagosome maturation,
counteract mycobactericidal molecules and ultimately survive
in a hostile intracellular environment (8–10). Therefore, the
search for new anti-TB agents that are able to safely penetrate
the host immune cells and eradicate the pathogen intracellularly
is now one of the priorities of global health action programs to
tackle tuberculosis.
The eventual outcome of a mycobacterial infection largely
depends on the readiness of the host immune system to
counter the pathogen. During infection a large assortment of
antimicrobial protein and peptides (AMPs) are released by
host immune cells to the bloodstream and nearby tissues to
the infected areas (11, 12). At the same time, neutrophil, and
eosinophil granules, loaded with lytic enzymes, and antimicrobial
molecules, can be acquired by macrophages to counter bacterial
invasion (13–15). Because AMPs exert a potent anti-infective
effect against a wide range of human pathogens and the likelihood
of microbial resistance is mostly reduced in comparison to
conventional antibiotics, they are emerging as a new generation
of natural lead candidates and its administration in combination
with or without other drugs is showing highly promising
results (16).
Abbreviations: DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine; DOPG,
1,2-dioleoyl-sn-glycero-3-phosphoglycerol); 3MA, 3 Methyadenine; MTT, 3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; AO, Acridine
orange; AMPs, Antimicrobial protein and peptides; BA, Bafilomycin A; CFU,
Colony forming unit; XDR, Extensively drug-resistant; FBS, Fetal bovine
serum; HTS, High-throughput screening; LUVs, Large unilamellar vesicles;
MB, Middlebrook; MAC, Minimum agglutination activity; MBC, minimum
bactericidal concentration; MIC, minimum inhibitory concentration; MOI,
Multiplicity of infection; MDR, Multi-drug resistant; Mtb, Mycobacterium
tuberculosis; NCTC, National Collection of Type Cultures; PMA, Phorbol
myristate acetate; SPOTi, Spot-culture growth inhibition assay; TEM,
Transmission electron microscopy; TB, Tuberculosis; ZN, Ziehl-Neelsen.
Our research group works on the mechanism of action of
human antimicrobial RNases, a group of proteins that belong
to the RNase-A superfamily. The family encompasses eight
functional members in humans, referred as the “canonical
RNases” (17). Among them, there are proteins secreted by
epithelial and blood cell types during host-defense response that
are endowed with the characteristic biophysical features of AMPs
(12, 18, 19). In particular, human RNase3, RNase6, and RNase7
are highly cationic proteins with reported antimicrobial activity
against a variety of microbes (20–23). Interestingly, secretion of
RNases 3 and 7 was associated toMycobacterium bovis (M. bovis)
BCG and M. tuberculosis infection, respectively (14, 24). Indeed,
both RNases displayed antimycobacterial activity in vitro (25).
In this work, we aimed to study the antimycobacterial activity
of the human canonical RNases by applying an integrated
surrogate model for screening of anti-tubercular drugs againstM.
tuberculosis (8). The semi-solid agar-based spot-culture growth
inhibition assay (SPOTi) has facilitated a rapid high-through
screening of antimicrobial agents against Mycobacterium aurum
(M. aurum) using a macrophage infected model (8, 26, 27).
M. aurum was chosen as a relatively fast-growing and stable
intracellular dwelling species within infected macrophages,
previously validated as an appropriate surrogate model for
Mtb (8). RNases with positive antimycobacterial activity were
further characterized by exploring their mechanism of action
in macrophages. The present results indicate that the protein
antimycobacterial action is partly mediated by the induction of
an autophagy process.
MATERIALS AND METHODS
Protein Expression and Purification
The cDNA for RNase1 was a gift from Prof. Maria Vilanova
(Universitat de Girona, Spain) and RNase5 from Prof. Demetres
Leonidas (University of Thessaly, Greece). RNase4 synthetic gene
was purchased from Nzytech company and RNase6 was obtained
from DNA 2.0 (Menlo Park, CA, USA). RNase2, RNase3, and
RNase7 genes were obtained as previously described (20). Active
site mutations into the RNases genes were introduced using the
Quick changeTM site-directed mutagenesis kit (Agilent, 200523)
following the manufacturers procedure (28). Escherichia coli
(E. coli) BL21 (DE3) (Novagen, 69450) competent cells were
transformed with the pET11c/RNase plasmids. Recombinant
proteins were expressed and purified in E. coli BL21 (DE3) by
an adaptation of the protocol previously described (20). Briefly,
E. coli BL21(DE3) cells were induced by 1mM isopropyl β-D-1-
thiogalactopyranoside (G Bioscience, RC-063) and the inclusion
bodies enriched pellet was resuspended in 80mL of 10mM
Tris-HCl pH 8.5, 2mM EDTA and left incubating 30min with
40µg/mL of lysozyme prior to sonication. Then, the sample was
centrifuged at 30.000 × g for 30min at 4◦C and the pellet was
resuspended in 25mL of the same buffer supplemented with
1% triton X-100 and 1M urea and was left stirring at room
temperature for 30min and centrifuged 30min at 22.000 × g.
Following, 200mL of 10mM Tris-HCl pH 8.5, 2mM EDTA
was added to the pellet, and then the sample was centrifuged
at 22.000 × g for 30min (4◦C). The resulting pellet solubilized
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in 6M guanidine hydrochloride and rapidly 80-fold diluted in
the refolding buffer was left in gentle stirring for 48–72 h at
4◦C. The folded protein was then concentrated, dialyzed against
the chromatography buffer and purified by cation exchange
chromatography on a Resource S column (GE Healthcare Life
Sciences, GE17118001). The identity and homogeneity of the
purified proteins were checked by SDS-PAGE, MALDI-TOF, and
N-terminal sequencing.
Macrophage Cell Culture
Mouse RAW 264.7 cells (NCTC, #91062702) and human THP-1
cells (NCTC, #88081201) were maintained or passaged in 25 cm2
tissue culture flasks (BD Biosciences, 353108) using DMEM
(Lonza, BE04-687F/U1) and RPMI-1640 (Lonza, BE12-702F)
medium with 10% heat-inactivated fetal bovine serum (FBS,
Gibco, 26140079) respectively at 37◦C and humidified 5% CO2
conditions. RAW 264.7 cells were seeded at 5 × 105 per well
and allowed to attach for 2 h before infection and treatment.
THP-1 cells were treated with 100 nM phorbol myristate acetate
(PMA, Sigma-Aldrich, P8139) for 48 h to induce differentiation
into macrophage-like cells and allowed to rest for 24 h before
further treatment. The number of viable cells was counted using
a Trypan blue (Invitrogen, 15250-061) exclusion assay.
Growth of Mycobacteria Culture and
Macrophage Infection
Mycobacterium aurum was purchased from the UK National
Collection of Type Cultures (NCTC). Cells cultures ofM. aurum
(NCTC, 10437), Mycobacterium smegmatis mc2155 (ATCC,
700084) andM. bovis BCG Pasteur (ATCC, 35734) were grown in
Middlebrook (MB) 7H9 broth (BDBiosciences, 271310) enriched
with 10% (v/v) albumin/dextrose/catalase (ADC; BDBiosciences,
212352) containing 0.05% Tween 80 and 0.05% Glycerol for
liquid growth at 37◦C for BCG, and inMB7H10 (BD Biosciences,
262710) with 10% (v/v) oleic acid/albumin/dextrose/catalase
(OADC; BD Biosciences, 212240) for semi-solid agar growth
at 37◦C. Stock cultures of log-phase cells were maintained in
glycerol (25% final concentration of glycerol) at −80◦C. The
bacteria were vortexed and sonicated using ultrasound sonication
bath to obtain a single cell suspension, and then the bacterial
concentration was determined by measuring the optical density
(OD) of the culture at 600 nm (1 OD =109 CFU/mL). Mid-
log phase M. aurum cells, harvested in RPMI-1640 complete
medium, were co-cultured with RAW264.7 or THP-1 at a
multiplicity of infection (MOI) of 10:1 and were incubated at
37◦C for 3 h, then were washed 3 times with PBS and replaced
with fresh media supplied with 50µg/mL gentamycin (Apollo
Scientific, BIG0124) to remove extracellular mycobacteria during
further treatment.
High Throughput SPOTi Assay, Minimum
Inhibitory Concentration (MIC), and
Minimum Bactericidal Concentration
(MBC) Assays
Antimicrobial activity of RNases was evaluated by calculating the
100% minimum bactericidal concentration (MBC100) and 100%
minimum inhibitory concentration (MIC100) in mycobacteria
cultures. The semi-solid agar-based SPOTi assay system was
applied for fast and high throughput screening and the colony
forming unit (CFU) counting assay for the validation and
accurate MBC/MIC100 determination (8). The MBC100 and
MIC100 of each protein was determined from two independent
experiments performed in triplicate for each concentration.
Briefly, log-phase cultures of mycobacteria (OD600≈1) were
first checked for quality control using cold Ziehl–Neelsen (ZN)
staining (also called “acid fast staining”; TB-color staining
kit, Merck Millipore, 116450) according to the manufacturer’s
protocol. For extracellular analysis, the mycobacterial cultures
were then diluted to 2 × 105 CFUs/mL and directly incubated
with proteins at 37◦C for 4 h in PBS in 1mL. For intracellular
analysis, the mycobacterial cultures diluted to 2 × 105 CFUs/mL
were used to infect macrophages and then treated with the
proteins for up to 72 h in RPMI-1640 medium with 10% FBS.
MIC100 were calculated at final incubation time. Uptake of
mycobacteria by RAW macrophages was confirmed using the
ZN staining assay, as described (8). No significant reduction
in the number of live macrophages was observed during the
experiment. Macrophage infection was monitored by CFUs
counting. Following the treatment, to evaluate the activity at
the protein extracellular activity the cultures were centrifuged
and suspended in 50 µL of distilled water and 5 µL of the
sample was spotted onto wells of a 24-well plate containing
MB7H10/OADC/agar. For evaluation of the protein intracellular
activity, the macrophages were washed twice with RPMI-1640
and lysed in water to harvest intracellular mycobacteria for
plating in 24-well plate (SPOTi) or 10mm petri dish (CFU assay).
Initial infection was adjusted to 2× 105 CFU/mL for all samples.
Mycobacterial cell growth at 37◦C was recorded after 2 days
for M. smegmatis, 4–5 days for M. aurum, and 14 days for M.
bovis BCG.
Minimum Agglutination Activity (MAC)
Assay
Mycobacterial cells were grown at 37◦C to an OD600 of 1.0
and diluted ten times. Then, cells were centrifuged at 5,000 ×
g for 2min, and resuspended in M7H9/ADC media containing
0.05% Tween-80 and 0.05% glycerol. An aliquot of 100 µl of
the mycobacterial suspension was treated with increasing protein
concentrations (from 0.01 to 25µM) and incubated at 37◦C for
1 h. The aggregation behavior was observed by visual inspection
with a stereomicroscope at 50x, and the agglutinating activity was
calculated as the minimum agglutinating concentration of the
protein, as previously described Pulido et al. (22).
Cytotoxicity Assay
To assay the toxicity of RNases to RAW264.7 macrophages, the
assay was performed in 96-well cell culture flat-bottom plates
(Costar; Appleton Woods) in triplicate. To each well, 100 µL
of diluted macrophage cells (5 × 105 cells/mL) were dispensed
in 96-well plates and then proteins were added serially at final
concentrations ranging from 0.01 to 50µM (100 µL/well) and
incubated for 48 h; cells were then washed twice with 1X PBS,
and fresh RPMI-1640 complete medium was added. Plates were
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then treated with 30 µL of a freshly prepared 0.01% resazurin
solution and incubated overnight at 37◦C. The following day the
change in color was observed and the fluorescence intensity was
measured (λem560, λex590 nm, FLUOstar OPTIMA microplate
reader; BMG LABTECH GmbH). The 50% growth inhibitory
concentration (IC50) was determined.
Tracking of RNases Internalization Into
RAW264.7 Macrophages by Confocal
Microscopy
RNase3, RNase6, and RNase7 were labeled with Alexa Fluor 488
Labeling kit (Invitrogen, A10235), following the manufacturer
′
s
instruction as previously described (21). To 0.5mL of 2 mg/mL
protein solution in PBS, 50 µL of 1M sodium bicarbonate,
pH 8.3, was added. The protein was incubated for 1 h at
room temperature with the reactive dye, with stirring, and
the labeled protein was separated from the free dye by PD-
10 desalting column (GE Healthcare, 17-0851-01). Labeled
protein distribution in cell cultures was followed by confocal
microscopy. About 2.5 × 105 RAW cells were harvested in
3 cm diameter microscopy plates (MatTek, P35G-1.5-14-C) 2–
3 h before the assay. Macrophages were washed with RPMI and
labeled with Hoescht 33342 (Thermo Fisher Scientific, 62249)
andCellMaskDeep Red Plasmamembrane Stain (Thermo Fisher
Scientific, C10046) at 0.5µg/mL for 5–10min before observation
in Leica TCS SP5 AOBS equipped with a PL APO 63 × 1.4–
0.6 CS oil immersion objective (Leica Microsystems, Mannheim,
Germany). Following, Alexa Fluor labeled proteins were added at
2µM to the cultures and time lapse was recorded at intervals of
30 s for 30min. Fluorochromes were excited by 405 nm (Hoechst
33342), 649 nm (CellMask Deep Red), and 488 nm (Alexa Fluor
488). Emissions were collected with a HyD detector.
Real-Time qPCR Assays
Total RNAwas extracted using mirVanaTMmiRNA Isolation Kit
as described by the manufacturer (Ambion, Life Technologies,
AM1560) at each time point (4, 24, 48, 72 h). Total RNA was
quantified by NanoDropTM spectrophotometer (Thermo Fisher
Scientific, Wilmington, DE USA), and cDNA was synthesized
using iScriptTM cDNA Synthesis Kit (Bio-Rad, 170-8891).
The unique ID of the primers used (synthesized by Bio-Rad,
Hercules, CA, USA) is shown in Table S1. Transcripts of human
RNase2, RNase3, RNase6, and RNase7 genes relative to the
human housekeeping GAPDH, and mouse BECN1 and ATG5
genes relative to mouse housekeeping β-actin were measured
in triplicate from cDNA samples by real-time quantitative
PCR using CFX96 Real-Time PCR detection system (Bio-Rad,
Hercules, CA, USA). The results were analyzed by using the
relative standard method (29).
Western-Blot Analysis
Expression level of the autophagy marker LC3 in RAW264.7
macrophages was evaluated by western blot analysis. Autophagy
was inhibited by addition of either 100 nM of Bafilomycin
A (BA, Sigma-Aldrich, 19-148) or 5mM of 3 Methyladenine
(3MA, Sigma-Aldrich, M9281) (30, 31). Rapamycin (Sigma-
Aldrich, R0395) at 100 nM was used as a positive control. When
the treatment was finished, cells were lysed by RIPA buffer
and the protein concentration was determined with the Pierce
BCA Protein Assay kit (Thermo Fisher Scientific, 23225). Equal
amounts of protein (50 µg) for each sample were loaded onto
a 15% SDS–PAGE gel. After the electrophoresis, proteins were
transferred to PVDF membrane. The membranes were blocked
and incubated with the primary antibody of interest. The primary
antibodies used were rabbit polyclonal anti-LC3 (1:1,000, Abcam,
ab48394) and chicken polyclonal anti-GAPDH (1:2,000, Abcam,
ab9483). After washing, a horseradish peroxidase-conjugated
antibody (Goat Anti-Rabbit IgG antibody, Sigma Aldrich, 12-348
and Goat anti-chicken IgY H&L, Abcam, ab6877) was applied
for detection using an enhanced chemiluminescent detection
system (Supersignal West Pico Chemiluminescent Substrate,
ThermoFisher Scientific, 32209). Densitometry analysis was
performed using Quantity One software.
Immunofluorescence Microscopy
RAW264.7 cells were grown, plated, and infected as above on
glass coverslip (5 × 105 cells each one). After fixation and
blocking, cells were incubated with the primary antibodies anti-
LC3 (1:200, Abcam, ab48394); the cultures were incubated for
1 h at room temperature with labeled secondary antibodies (1:
500, anti-rabbit IgG-Alexa Fluor 488, ThermoFisher Scientific,
A-11008) and then washed 3 times with PBS. Cells were
incubated with Hoechst (ThermoFisher Scientific, 62249) and
Cell Mask Deep Red (Invitrogen, C10046) to visualize the
nuclei and membrane, and then were loaded with mounting
media and sealed with nail oil. Images were captured by Leica
TCS SP5 AOBS microscope equipped with a PL APO 63
× 1.4–0.6 CS oil immersion objective (Leica Microsystems,
Mannheim, Germany). Quantification of fluorescence intensity
was performed by using Imaris software.
Alternatively, to quantify LC3 accumulation RAW264.7 cells
were plated on glass coverslip (5 × 105 cells each one) and
treated with RNase3 and/or Bafilomycin A. After treatment,
cells were fixed with 2% paraformaldehyde, permeabilized
with 0.05% triton-X100, and blocked with 5% non-fat milk.
Cells were incubated with the primary antibodies anti-
LC3 at 4◦C overnight (1:200, Abcam, ab48394), and room
temperature 2 h with secondary anti-rabbit IgG-Alexa 488
antibody(ThermoFisher Scientific, A-11008) and then washed 3
times with PBS. Cells were stained with DAPI (ThermoFisher
Scientific, 62248) to visualize the nuclei for 30min at room
temperature and then were loaded with mounting media and
sealed with nail oil. Images were captured by Leica DM RB
equipped with a Leica DFC 500 camera under 100-fold oil
objective. LC3 puncta vesicle quantification was performed
using Image J.
Transmission Electron Microscopy
For transmission electron microscopy (TEM) analysis, 106
infected RAW264.7 macrophages cells were seeded in 6-well
tissue culture plates and were treated with 10µM RNase3 or
RNase3-H15A for 24 h. After treatment, macrophages were fixed
with 2% (w/v) paraformaldehyde and 2.5% (v/v) glutaraldehyde
in PBS for 1 h. The samples were then dehydrated in acetone (50,
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70, 90, 95, and 100%) and were immersed in Epon resin (32). The
ultrathin sections were examined in a JEOL JEM 2011 instrument
(JEOL, Ltd., Tokyo, Japan).
Acidic Vesicular Compartment
Quantification by the Acridine Orange
Assay
To quantify the volume/amount of the acidic vesicular
compartment, RAW264.7 macrophage cells were treated
with the proteins and were stained with acridine orange (AO,
ThermoFisher Scientific, A1301) as previously described (33).
Briefly, cells were seeded in 96-well plates (104 cells/well)
and treated with RNases for 24 h. Rapamycin (100 nM) was
used as a positive control and BA (100 nM) was used as an
inhibitor of acidification of vesicular content. At the end of
the treatments, cells were washed with pre-warmed PBS and
stained with 5µg/mL AO for 10min in PBS. After washing
with PBS three times, the increase in the amount of the
acidic vesicular compartment was quantified by measuring the
red/green fluorescence intensity ratio of AO staining (AO green
fluorescence λexc 485 and λem 535 nm; AO red fluorescence
λexc 430 and λem 590 nm). Values were normalized by cell
proliferation count by the Thiazolyl Blue Tetrazolium Bromide
(MTT, Sigma-Aldrich, M5655-100MG) assay.
FIGURE 1 | A representative SPOTi image comparing human RNases activity on Mycobacterium aurum infected macrophages. RAW 264.7 macrophages were
infected with M. aurum at 10:1 MOI for 3 h at 37◦C. The culture was washed with RPMI-1640 thrice and incubated with different concentrations of the proteins in
RPMI-1640 complete medium for 4 h (Left) or 24 h (Right). Macrophages were washed twice with RPMI-1640 and lysed. Then, an aliquot was spotted onto wells of a
24-well plate containing MB7H10/OADC/agar and incubated at 37◦C for 4–5 days to determine intracellular survival.
TABLE 1 | Comparison of the antimycobacterial activity of RNase3, RNase6, and RNase7 and their respective active center mutants (H15A).
Protein Extracellular MBC (µM) MAC (µM) Intracellular
MIC (µM)
IC50
(µM)
M. aurum M. smegmatis
mc2155
M. bovis BCG M. aurum M. smegmatis
mc2155
M. bovis
BCG
M. aurum RAW264.7
RNase3 18.75 ± 0.05 9.37 ± 0.05 18.75 ± 0.05 2.34 ± 0.5 1.17 ± 0.3 4.68 ± 1.0 5 ± 0.05 > 25
RNase3-H15A 18.75 ± 0.05 18.75 ± 0.05 18.75 ± 0.05 4.68 ± 0.5 4.68 ± 1.0 4.68 ± 1.0 10 ± 0.05 > 25
RNase6 18.75 ± 0.05 18.75 ± 0.05 18.75 ± 0.05 4.68 ± 1.0 2.34 ± 0.5 4.68 ± 1.0 10 ± 0.05 > 25
RNase6-H15A 18.75 ± 0.05 18.75 ± 0.05 37.5 ± 0.05 4.68 ± 1.0 2.34 ± 0.5 4.68 ± 1.0 10 ± 0.05 > 25
RNase7 18.75 ± 0.05 18.75 ± 0.05 18.75 ± 0.05 > 10 > 10 > 25 10 ± 0.05 > 25
RNase7-H15A 18.75 ± 0.05 18.75 ± 0.05 18.75 ± 0.05 > 10 > 10 > 25 10 ± 0.05 > 25
Extracellular minimum bactericidal concentration (MBC100) and intracellular minimum inhibitory concentration (MIC100) were calculated at 72 h incubation time using the SPOTi assay.
Minimum agglutination concentration (MAC) and Inhibitory Concentration (IC50) for RAW 264.7 mouse macrophages were assayed as described in the methodology. Results are an
average of three independent repeated experiments. Mean average values ± SD are indicated.
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Liposome Aggregation Assay
Large unilamellar vesicles (LUVs) were prepared as
previously described (20). Briefly, 1,2-dioleoyl-sn-glycero-
3-phosphocholine (DOPC, Avanti, 850375) and 1,2-dioleoyl-sn-
glycero-3-phospho-(1’-rac-glycerol) (DOPG, Avanti, 840445P)
were mixed in chloroform with 3:2 molar ratio and used
to prepare LUVs by Rotavapor. Then the liposomes were
resuspended with 10mM Tris/HCl, pH7.4 and generated
a defined size (100 nm) by extrusion through 100 nm
polycarbonate membranes.
Aggregation of liposomes was monitored by recording
the scattering intensity with the excitation and emission
wavelengths at 470 nm using Cary Eclypse spectrofluorimeter.
Liposomes were incubated with proteins for indicated
time at room temperature, the signal was read 90
degree from the excitation beam with slits at 2.5
and 5 nm.
Statistical Analysis
Data are presented as mean ± SD and comparisons between
groups were analyzed by paired Student t-test and one-way
ANOVA for comparing more than 2 groups. p < 0.05 was
considered as statistically significant.
RESULTS
Screening of Human Canonical RNases
Identifies Three Members With
Antimycobacterial Activity at Extracellular
and Intracellular Levels
In this work we have evaluated for the first time the antimicrobial
potency of the seven human RNases from the RNase A
superfamily using the SPOTi surrogate model adapted for the
screening of novel anti-TB drug candidates (8). Previous work
in our laboratory selected M. aurum as a fast non-pathogenic
species suitable for the screening of anti-tubercular drugs at the
extracellular (directly on mycobacterial culture) and intracellular
(on mycobacteria residing inside infected macrophage cell-line)
levels, referred in this article as in vitro and ex vivo assays,
respectively. Screening results indicated that RNase3, RNase6
and RNase7 can completely inhibit the growth of M. aurum
cultures at a low micromolar concentration range, while the
rest of the RNases did not reduce the mycobacteria population
even at the highest concentration tested (Figure S1). Next,
we assayed the antimicrobial activity of the seven human
RNaseA protein family members againstM. aurum within RAW
264.7 mouse macrophages. Results from the screening of the
seven human secreted RNases confirmed that only RNase3,
RNase6 and RNase7 are active against mycobacterial infection
(Figure 1). Interestingly, when comparing the reduction of
CFU counts in comparison to control untreated samples
for in vitro and ex vivo conditions we observed that the
effectiveness of the protein was higher at the intracellular level
(ex vivo assay) (Table 1). Besides, comparison of the macrophage
intracellular antimycobacterial activity at 4 and 24 h indicated
that the protein activity is enhanced at longer incubation
times. Total inhibition of intracellular M. aurum growth was
achieved at about 2-fold lower protein concentration at 24 h
incubation time in comparison to 4 h (Figure 1). Monitoring
of the protein activity within infected macrophages up to
72 h also revealed an increase of the antimicrobial efficiency
at longer exposure times. The results suggested that other
mechanisms, together with a direct killing of the bacilli, are
taking place.
FIGURE 2 | Tracking the translocation of Alexa Fluor 488-labeled RNase3 into RAW 264.7 mouse macrophages. (A) macrophages cells were stained with Hoechst
and Deep Red to visualize the nuclei (blue) (B) and membranes (red) (C), respectively. (D) The protein location was registered after 30min of macrophages
post-treatment with Alexa Fluor 488-RNase3 (green). A panel showing merged images is shown in (E). Protein tracking assays were performed using 2.5 × 105
cells/mL and adding 2µM of labeled protein final concentration. The images were taken using a Leica TCS SP5 AOBS microscope (see Materials and Methods
section for more details).
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The Enzymatic Activity Is Not Involved in
the RNases Antimycobacterial Activity
Following, RNase3, RNase6, and RNase7 were chosen to further
investigate whether the enzymatic activity contributes to the
antimycobacterial properties of human RNases by comparing the
recombinant native proteins with their catalytic inactivemutants.
Previous work from our laboratory confirmed that the H15A
substitution fully removed the catalytic activity without altering
the protein 3D-structure (28). First, the three antimicrobial
proteins (RNases 3, 6, and 7) together with their respective active
site mutants (H15A) were tested in vitro against M. smegmatis
mc2155,M. aurum andM. bovis BCG. As summarized inTable 1,
RNase3, RNase6, and RNase7 showed similar antimicrobial
activities against the three mycobacteria species. Then,M. aurum
FIGURE 3 | Human RNases 3 and 6 induce macrophage autophagy. RAW
264.7 macrophages were infected with M. aurum and treated with 10µM of
proteins (RNase1 to RNase7) for 24 h. Real-time qPCR measured the relative
expression of BECN1 (A) and ATG5 (B) genes normalized by housekeeping
gene β-actin. Results are shown from 3 independent experiments (mean ±
SD); (C) Immunoblot of LC3-processing and the housekeeping GAPDH
control. Results are shown from 3 independent experiments (mean ± SD).
*Statistically significant differences compared with the control sample are
indicated (p value < 0.05).
species was chosen for macrophage intracellular studies, being
among the three tested species the only one that provides a fast
growing profile together with an efficient macrophage uptake
(8). Overall, no significant differences were observed between
the native proteins and their respective active site mutants
against M. aurum, both at the extracellular and intracellular
levels. Therefore, we can conclude that the three RNases can
eradicate M. aurum dwelling within the macrophage at a low
micromolar concentration range. To note, RNase3 stands out
as the most active, achieving mycobacterial growth inhibition at
5µM (Table 1).
Next, we tested the agglutinating activity of the RNases against
the three assayed mycobacterial species. The agglutinating
activity was calculated as the minimum agglutinating
concentration (MAC). Results indicated that RNase3 and RNase6
can agglutinate mycobacteria within the same concentration
range, while RNase7 is not active even at the maximum
concentration tested. Besides, there were no significant
differences among the MAC values of the wild type and active
site mutants (Table 1). From our findings, we can infer that
catalytic activity of the ribonucleases is not involved in their
antimycobacterial mode of action.
Tracking the Protein Internalization Within
Macrophages
Following, the RNases internalization within macrophages was
visualized by confocal microscopy. Results confirmed that
the three RNases are able to internalize within the mouse
macrophages through a vesicle-mediated mechanism (Figure 2).
Analysis of the profiles of selected regions of interest confirmed
the protein confined location within macrophage vesicles
(Figures S2, S3). In addition, time-lapse assays indicated that
internalization is a fast process, where most of the protein
enters into the macrophage within the first 30min. Examples of
internalization fluorescence profiles of labeled RNase3, RNase6,
and RNase7 were recorded at several time intervals (Figure S4).
Confocal microscopy images confirmed that no damage to the
macrophage cells at the assayed conditions was taking place.
Besides, the protein toxicity on the mouse macrophages in the
assayed conditions was also discarded by using the resazurin
assay; no significant cytotoxicity was observed at the maximum
concentration tested (25µM) (Table 1).
M. aurum Infection Modulates the
Expression of RNases in THP1
Macrophage Differentiated Cells
Encouraged by positive results on the antimycobacterial activity
of recombinant RNases we decided to test whether the
mycobacteria infection can induce the protein expression
in human macrophages. We selected the human monocyte
THP1 cell line differentiated to macrophages and infected it
with M. aurum. Levels of expression of human RNases were
evaluated by real time qPCR. Primers of the four known
antimicrobial RNases expressed in blood cell type were used
to quantify their transcription levels (Table S1). Transcription
levels were quantified in relation to the GAPDH housekeeping
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gene. Results indicated that both control macrophage derived
THP1 cells and M. aurum infected cells expressed the tested
RNase genes (Figure S5). However, the protein transcription
rates differed significantly among the RNases. Results of non-
infected THP1 cells were in agreement with previous expression
profile reports showing the predominant transcription of RNase2
(18). Comparison of the relative expression levels highlighted
also the significant quantities of RNase6 followed by RNase3.
On the contrary, RNase7 expression was very scarce, more
than 1,000-fold lower than RNase2. Interestingly, M. aurum
infection modulated the expression of RNase3 and RNase6, while
RNase2 transcription levels remained unaffected (Figure S5). In
addition, analysis of the expression profiles as a function of
time also highlighted significant differences between early and
late infection periods. Overall, M. aurum infection significantly
inhibited the THP1 cells expression of RNases at the beginning
of the infection (24 h), but triggered their expression at longer
infection periods (48–72 h).
RNases 3 and 6 Induce Autophagy in
Macrophages
Autophagy is one of the main mechanisms activated by infected
macrophages to remove intracellular resident mycobacteria
(34). Considering that some AMPs are known to participate
in the host immune response against mycobacteria by the
activation of autophagy (12), we decided to explore the action
of human RNases on infected macrophages. RAW 264.7 mouse
macrophages were chosen as a stable well-characterized cell
line for the analysis of the recombinant proteins. First, we
tested whether the human RNases could induce the expression
of the autophagy markers BECN1 and ATG5, two essential
genes involved in autophagosome formation and maturation,
respectively. Analysis of qPCR results indicated that RNase3
and RNase6, out of the seven screened RNases, significantly
upregulated the mRNA expression of BECN1 and ATG5 in
RAW 264.7 macrophages (Figures 3A,B). These positive results
were corroborated by analysis of LC3 processing and detection
of the LC3II form, involved in the autophagosome formation
(35). LC3 transformation was also evaluated by immunoblotting,
confirming an increase in the LC3II fraction in detriment of LC3I
in RNase3 and RNase6 treated samples in comparison to control
(Figure 3C). Therefore, we conclude that both RNases activate an
autophagy process in the treated macrophages.
RNase Catalytic Activity Is Not Required
for the Protein Autophagy Activation
We then analyzed in more details the protein activation
of the autophagy pathway by using as a reference RNase3,
the most active family member. First, the RNase3 wild-type
ability to induce autophagy was compared with the RNase3-
H15A enzymatically inactive variant by following the expression
of BECN1 and ATG5 and monitoring the LC3II/LC3I ratio
(Figure 4). Equivalent activity of both wild-type and H15A
mutant proteins discards any contribution of the enzyme
catalytic activity in the autophagy pathway activation.
FIGURE 4 | Both RNase3 and the RNase-H15A active site mutant induce
autophagy in macrophages. RAW 264.7 mouse macrophages were infected
with M. aurum and treated with 10µM of protein (RNase3 and RNase3-H15A).
Real-time qPCR measured the relative expression of BECN1 (A) and ATG5 (B)
genes normalized by the housekeeping gene β-actin. Results are shown from
3 independent experiments (mean ± SD); (C) Immunoblot of LC3-processing
and the housekeeping GAPDH control. Results are shown from 3 independent
experiments (mean ± SD). *Statistically significant differences compared with
the control sample are indicated (p value < 0.05).
In addition, LC3 transformation was monitored by
immunofluorescence microscopy after treatment of M. aurum
infected RAW macrophage cells with either RNase3, RNase3-
H15A, or rapamycin, used as a positive control of autophagy
induction, observing in all cases a significant increase of LC3
intensity (Figures 5A,C). Complementarily, we applied TEM
to visualize the ultrastructure of mouse macrophages infected
with M. aurum and treated with RNase3 and RNase3-H15A.
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FIGURE 5 | RNase3 and RNase3-H15A induce autophagic vacuole formation and LC3 processing. (A) Immunofluorescence microscopy analysis of LC3 processing,
Mouse macrophages were infected with M. aurum and treated with 10µM of RNase3, or 10µM RNase3-H15A mutant, or 100 nM Rapamycin for 24 h. After
treatment, the cells were fixed and stained with Hoechst to visualize the nuclei (blue), and with anti-LC3 followed by the addition of Alexa Fluor 488-conjugated
anti-rabbit IgG (green). One representative immunofluorescence image out of 3 independent replicates are shown; scale bars: 10µm; (B) Representative transmission
electron microscopy images of M. aurum infected RAW264.7 cells treated with 10µM RNase3 or 10µM RNase3-H15A. Autophagic vacuoles are indicated by white
arrow; (C) Quantitative analysis of LC3 intensity normalized with cell volume from 3 replicates. Results are shown from 3 independent experiments (mean ± SD).
*Statistically significant differences compared with the control sample are indicated (p value ≤ 0.05). (D) total number of autophagic vacuoles per cell for 30 cells
randomly selected per each treated sample. Autophagic vacuoles were defined as double-membrane vacuolar structures containing recognizable
cytoplasmic contents. *Statistically significant differences compared with the control sample are indicated (p-value ≤ 0.05).
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Inspection of electron micrographs revealed a higher number
of double-membrane vacuoles in both RNase3 and RNase3-
H15A treated macrophages in comparison with the control
group (Figures 5B,D). Thus, the enzymatic activity is not been
involved in the RNases autophagy induction process.
The Protein Autophagy Induction
Correlates With Vesicles Agglutination
Activity
Accumulation of double-membrane vacuoles, associated to the
autophagosome formation, constitutes a characteristic trait of the
autophagy pathway (36). Together with the initial autophagic
vacuoles we could also identify abundant single-membrane
degradative vacuoles, that could be ascribed to autolysosomes
and are characteristic of the later steps of the autophagy process
(Figure 5B). Moreover, macrophage incubation with RNase3
presented a dose dependent increase in the total volume of
acidic vesicular compartments, as quantified by registering the
AO acidotropic dye signal, a trait associated to autolysosome
formation (Figure S6). In contrast, no significant change in AO
signal was recorded for the none-autophagic RNase7, used here
as a negative control. Rapamycin was used as a positive control
and addition of BA, an inhibitor of the vacuolar H+ -ATPase,
resulted in a significant reduction of the AO signal.
To note, the two RNases that activate autophagy, RNase3 and
RNase6, can agglutinate liposome vesicles, in contrast to RNase7
(Figure S7). Likewise, RNases 3 and 6, but not RNase7, have
mycobacteria cell agglutination activity (Table 1). The results
suggest that the protein agglutination activity might be involved
in the autophagy induction process.
Induction of Macrophage Autophagy
Contributes to RNase Antimycobacterial
Activity
Next, the induction of the autophagy process was confirmed
for wild-type and mutant proteins in both infected a non-
infected macrophages. The levels of the autophagy markers
in RNase3 treated samples were also compared to rapamycin,
observing in all cases comparable levels of BECN1 and ATG5
expression and LC3II/LC3I ratio (Figure 6). Induction of
autophagy by RNase3 was reproduced on both control and
infected macrophages (Figure 6). Results also corroborated that
there were no significant differences between the effect induced
by wild-type RNase3 and the H15A mutant variant on both
infected and non-infected macrophage populations.
Following, we evaluated whether the RNase induction of
autophagy mediates the protein macrophage intracellular killing
of mycobacteria. First, the levels of autophagy markers
(BECN1, ATG5, and LC3-II) were quantified following
RNase3 treatment in the absence and presence of autophagy
inhibitors (3methyladenine and bafilomycin A1). 3MA is
an early inhibitor of the autophagy pathway and works by
blocking the autophagosome formation, whether BA arrest
the autophagic process in a later step by impeding the
autophagosome maturation and subsequent fusion with the
lysosome compartment. Accordingly, while the presence of 3MA
FIGURE 6 | RNase3 and RNase3-H15A induce autophagy in control and M.
aurum infected macrophages. Mouse macrophages were uninfected or
infected with M. aurum and treated with 10µM of protein (RNase3,
RNase3-H15A) or 100 nM Rapamycin for 24 h. Real-time qPCR measured the
relative expression of (A) BECN1 and (B) ATG5 genes normalized by the
housekeeping gene β-actin. Results are shown from 3 independent
experiments (mean ± SD); (C) Immunoblot of LC3-processing and the
housekeeping GAPDH control. Results are shown from 3 independent
experiments (mean ± SD). *Statistically significant differences compared with
the control sample are indicated (p-value < 0.05).
blocked the RNase3 induction of autophagy, no reduction in the
expression levels of the autophagy markers were observed in the
samples treated with BA (Figures 7A–C). In fact, quantification
of LC3 accumulation by immunofluorescence microscopy
revealed a significant increase of LC3 puncta per cell when
macrophages were incubated with RNase3 in the presence
of BA (Figure 8).
More interestingly, both autophagy inhibitors reduced
significantly the protein ability to kill mycobacteria within
macrophages (Figure 7D, Figure S8). The fact that 3MA
inhibits RNase3 induction of autophagy, but not BA treatment,
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FIGURE 7 | Autophagy induction by RNase3 contributes to its antimycobacterial activity against M. aurum. Mouse macrophages were infected with M. aurum and
treated with 5µM of RNase3 and/or 100 nM of rapamycin, and/or 100 nM of bafilomycin A1, and/or 5mM of 3 methyladenine for 24 h. Real-time qPCR measured the
relative expression of BECN1 (A) and ATG5 (B) genes normalized by the housekeeping gene β-actin. Results are shown from 3 independent experiments (mean ±
SD); (C) A representative immunoblot of LC3 and housekeeping GAPDH control; (D) Intracellular mycobacterial viability was determined based on the number of
CFUs. Relative percentages to control samples are indicated. Results are shown from 3 independent experiments (mean ± SD). *Significant differences between pairs
is indicated (p value < 0.05).
suggests that the protein triggers the onset of the autophagy
process. Moreover, BA reduced the protein ability to kill
the intracellular mycobacteria, indicating that the RNase anti-
infective activity is partly dependent on the maturation of the
autophagosome. Likewise, rapamycin co-treatment with RNase3
enhanced the protein antimicrobial effectivity (Figure 7D). An
equivalent pattern was reproduced by the RNase3-H15A mutant
(Figure S8). Therefore, the results confirm that the induction of
autophagy participates in the RNase3 antimycobacterial activity
within infected macrophages.
DISCUSSION
Previous studies have demonstrated that macrophages serve as a
major protecting niche for dormantmycobacteria that can trigger
a later reactivation from the disease latency. This scenario is
one of the main hindrances in developing effective eradication
of tuberculosis. Antimicrobial peptides participate in the host
innate immunity against macrophage dwelling TB bacilli (12).
Currently, the fight against emergent MDR-TB-forms is at the
top priority of global health action programs (1). Within this
context, the search for novel anti-TB agents is a priority. In
this work, we have taken profit of our developed screening
platform adapted for testing the drug efficacy within infected
macrophage cells. The SPOTi high-throughput screening (HTS)
assay system uses a non-pathogenic fast-growing mycobacterial
species (M. aurum) able to survive within RAW 264.7 mouse
macrophages, as a surrogate model for host TB infection.
M. aurum is an appropriate substitute forM. tuberculosis among
other non-pathogen mycobacteria candidates sharing a similar
cell-wall structure, gene organization, and drug resistance pattern
(8, 26, 27). The SPOTi assay was applied to screen the seven
main canonical human members of the RNase A superfamily.
The human canonical RNases, although sharing a high sequence
identity and a conserved structural fold (Figure S9), differ
considerably in their biological properties. Overall, RNases
are secreted by different types of innate immune cells and
participate in a variety of endogenous processes involved in
the host defense (18, 28, 37, 38). One of the main ascribed
tasks for human secretory RNases is the safeguard of the body
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FIGURE 8 | Comparative analysis by immunofluorescence microscopy of LC3 accumulation following RNase3 treatment in the absence and presence of Bafilomycin
A. Mouse RAW264.7 cells were incubated with 10µM RNase3 and/or 100 nM of Bafilomycin A1. Primary anti-LC3 antibody and Alexa-488 labeled secondary
antibody were used to detect LC3 (green). Nuclei were labeled with DAPI (blue). Following immunostaining, 100 cells from each treatment were analyzed and the
number of LC3 puncta per cell was calculated by Image J. *Statistically significant differences are indicated, p < 0.05.
fluid sterility. A diversity of anti-infective activities have been
reported for some family members (18, 39–42). Among them,
the protein mechanism of action on bacterial cells is probably
one of the best studied processes (37, 38, 43). In particular,
previous works identified the involvement of RNases 3 and 7 in
mycobacterial infection. Expression of RNase3 together with α-
defensin inM. bovis BCG infection was first reported by Capron
and coworkers (14). Interestingly, the researchers observed the
specific recruitment and induction of eosinophils by lipomannan,
a unique mycobacterial cell-wall component. Very recently,
Rivas-Santiago and coworkers reported the overexpression of
RNase7 in airway epithelial cells infected by M. tuberculosis
(24). In our laboratory we have confirmed the antimycobacterial
activity of recombinant RNase3 and RNase7 on M. vaccae
in vitro and characterized the protein mechanism of action at the
bacterial cell-wall (25).
In this work, we have screened the antimycobacterial activity
of the seven main canonical RNases. Taking advantage of
the SPOTi-HTS, the protein activities were simultaneously
assayed in vitro and ex vivo (8, 26, 27). Results indicated
that out of the seven tested human RNases only three were
active against both extracellular and intracellular macrophages-
dwelling mycobacteria (Figures 1, 2). A high antimycobacterial
activity was observed for RNases 3, 6 and 7, while RNases 1, 2,
4 and 5 were found inactive even at the highest concentration
tested. The three active RNases (RNases 3, 6, and 7) correspond
to the family members with previously reported antimicrobial
activity against Gram-negative andGram-positive species (37, 38,
41). The present data corroborate that RNase3 is the most active
among the family members.
Following, the three active RNases (RNases 3, 6, and
7) were selected for further analysis. First, the minimum
bactericidal activity was determined in vitro against three distinct
Mycobacterium species:M. smegmatismc2155,M. aurum andM.
bovis BCG (Table 1). In addition, the protein cell agglutination
activity was tested against the three assayed mycobacteria
species (M. smegmatis mc2155, M. aurum, and M. bovis BCG).
Interestingly, RNases 3 and 6 were able to induce the aggregation
of all the tested mycobacteria, but not RNase7 (Table 1). The
results are in accordance with our previously published data
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using M. vaccae cultures, where RNase3, but not RNase7,
showed a significant mycobacterial cell agglutination activity
(25). Previous works from our laboratory on Gram-negative
species also revealed the agglutination ability of RNases 3 and
6 in contrast with RNase7 (21, 38). Likewise, RNases 3 and 6
can agglutinate phospholipid vesicles but not RNase7 (Figure S7)
(20, 38). Positive agglutination was correlated with the presence
of an aggregation-prone hydrophobic patch within the primary
sequences of RNases 3 and 6 (37, 44–46). Comparative scanning
of the three RNases profiles using the AGGRESCAN 3D software
(47) also highlighted the absence of an aggregation patch
at the RNase7 structure surface (Figure S9). On the other
hand, no significant differences were observed between the
wild-type and H15A mutants of the three RNases showing
antimycobacterial activity (Table 1). The present results on
mycobacteria confirm previous studies on Gram-negative and
Gram-positive bacterial species that indicated that the RNases
catalytic activity did not participate in their antimicrobial action
(37, 38, 48–51).
To evaluate the potential translational significance of our
results in an in vivo scenario, we analyzed the expression levels
of the RNases in human macrophage THP1 cells following
M. aurum infection. To this end, we synthesized primers for
the four human family members with described anti-pathogen
activities and previously reported to be expressed in granulocytes
(18). Our data highlighted that the human monocyte-derived
THP1 macrophages primarily expresses RNase2 and secondarily
RNase3 and RNase6, while a very scarce expression of RNase7
is detected (Figure S5). This expression pattern corroborates
previous studies that highlighted a predominant expression of
RNase2 in human monocytes. On the other hand, RNase7
was reported to be abundantly expressed in epithelial cells
(52) but poorly in macrophages (23). In addition, Becknell
and co-workers reported a regulation of RNase6 expression
in macrophages in response to uropathogenic E. coli infection
(23). The present data indicates that M. aurum infection is
only altering the expression profile of cultured macrophages for
RNase3 and RNase6 genes. However, further work would be
needed to characterize the RNases expression pattern in primary
macrophages. The results are in accordance with the previously
observed anti-pathogen properties of the three detected RNases.
RNase2 has a high antiviral activity but no antibacterial activity
in vitro, and is regulated during viral infection (40). On their
turn, RNases 3 and 6 have a high bactericidal activity and
their expression is regulated by bacterial infections (18, 23,
42). The present time-course expression profiles in M. aurum
infected THP1 macrophages indicates a downregulation of
RNase3 and RNase6 after a short infection period followed by a
significant upregulation at longer incubation times. Modulation
of antimicrobial RNases following M. aurum infection are in
agreement with previously reported results usingM. tuberculosis
(18, 24). In the literature there are other examples of AMPs
downregulated upon mycobacteria infection, a process induced
by the Mtb bacilli as a protection mechanism against the host
innate armory (12, 30). On its turn, upon infection, the host
immune cells activate the expression of antimicrobial proteins
and peptides (12, 53). Many stimuli have been reported to
regulate the expression of human RNases, such as bacterial,
viral or parasite infection together with inflammation, sepsis
and tissue damage (18, 42, 54). Intriguingly, the comparative
expression pattern of the distinct RNaseA members reveals a
clear specialization in regard to innate cell and infection types
(18, 55). In this context, RNase7 is mainly secreted by epithelial
tissues and conforms a protection barrier against bacterial
intruders, whereas RNases 3 and 6 are abundant in blood cell
types. In particular RNase 3 is highly expressed in eosinophils
while RNase6 predominates in neutrophils and monocytes
(18). In addition, free secretory granules from eosinophils and
neutrophils can be engulfed bymacrophage cells and release their
content within (18, 56, 57).
Our present results using murine RAWmacrophages infected
with M. aurum highlighted that the three antimicrobial RNases
can effectively eradicate the macrophage intracellular resident
mycobacteria at a 5 to 10µM range (Table 1). The fact that the
RNases could more easily eradicate the mycobacteria resident
within macrophages than free in extracellular cultures suggested
us that the proteins might combine a direct bacterial cell killing
action with some other biological properties.
Immunomodulatory activities mediate the antimycobacterial
action of many AMPs (12, 58–60). One of the main strategies
undertaken by AMPs to control the proliferation of macrophage
intracellular resident bacteria relies on the triggering of the
autophagy pathway (12, 30, 34, 61–63). Selective autophagy
targeting invading pathogens contributes to maintain the host
tissue homeostasis (64). On its turn, the Mtb bacilli ensure
their intracellular survival within macrophages by arresting
the autophagosome maturation (65, 66). Therefore, autophagy
inducers are among the favorite drug candidates against resistant
TB strains (12, 34, 58, 59, 62, 67). Interestingly, out of
the seven screened RNases, RNase3, and RNase6 significantly
increased BECN1 and ATG5 gene expression and LC3 processing
was observed (Figure 3). Subsequent analysis using RNase3
as a reference indicated that the autophagy induction process
is unrelated to the protein catalytic activity (Figures 4, 5).
Moreover, the autophagy induction was reproduced in both
infected and non-infected macrophages (Figure 6).
The contribution of autophagy induction on the RNase3
antimycobacterial activity was corroborated by evaluating the
protein effect on M. aurum growth upon blockage of the
autophagy pathway. The blockage of the autophagosome
formation or maturation was induced by either addition of
3MA, an inhibitor of the PI3K class III kinase (68), or BA, an
ATPase inhibitor that prevents the lysosome fusion with the
autophagic vesicles (69). When the infected macrophages were
treated with RNase3 in the presence of either 3MA or BA we
observed a reduction in the protein inhibitory activity of M.
aurum growth (Figure 7 and Figure S8). On the other hand,
rapamycin enhanced the antimycobacterial activity of RNase3.
The same pattern was reproduced when assaying the RNase3-
H15A mutant action in the presence of the autophagy inhibitor
or activator (Figure S8).
The fact that BA does not inhibit the RNase induction of
autophagy but reduces its antimycobacterial activity suggests
that the protein action is dependent on the late autophagosome
maturation process. Moreover, upon cell incubation with RNase3
we observed an increase in the acidic vesicle content (Figure S6),
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a process that can be associated to autolysosome formation.
To note, other AMPs, such as azurodicin and calgranulin,
activate autophagy by promoting the autophagosome fusion
with lysosomes (12, 53, 70, 71). Overall, our results confirm
that autophagy contributes to the RNase antimycobacterial
mechanism of action. However, the fact that addition of the
autophagy inhibitors does not fully abolishes the antimicrobial
activity of the protein indicates that other biological properties
are also participating in its antimycobacterial activity. In
addition, considering that RNases 3 and 6 induce autophagy,
but not RNase7, and that no significant differences are observed
between the wild type and the active site mutant proteins, we
can suspect that the protein aggregation-prone ability might be
involved in the autophagy pathway. Indeed, our previous results
correlated the protein self-aggregation capacity with the proteins
lipid vesicle agglutination and membrane disruption ability (20).
We can speculate that the formation of protein aggregates could
promote the autophagosome formation and later fusion with
the lysosomal compartment. Complementarily, other protein
properties, such as high cationicity, were considered to underlie
the autophagy process. The predicted isoelectric point (pI) for
all tested seven RNases, ranging from 9 to 10.7 (Table S2),
emphasizes their prominent cationicity, a characteristic trait
of AMPs (72–74). However, although RNase3 is the most
cationic of all the proteins, we cannot find a direct correlation
between the pI and antimicrobial or autophagy induction abilities
among the seven tested human RNases. Likewise, the protein
hydrophobicity was analyzed, obtaining very similar calculated
GRAVY values (Table S2). Further work is ongoing to unravel the
structural determinants underlying the RNase antimycobacterial
mechanism of action.
Interestingly, two RNaseA family homologs (bovine seminal
RNase and onconase) were recently reported to exert their anti-
tumoral activity by the selective induction of the autophagic
cancer cell death (33, 75). Bovine seminal RNase (BS-RNase)
triggers an autophagic cell death process in pancreatic cancer
cells mediated by BECN1 induction; and onconase, a RNaseA
superfamily member proposed for chemotherapy, inhibits the
proliferation of cancer cells through the ROS/Akt/mTOR
pathway (33, 75). Surprisingly, the bovine pancreatic RNaseA,
displaying a high catalytic activity and sharing about a 82%
sequence identity with BS-RNase, could not reproduce the
induction of autophagy. The authors associated the activation
of the autophagic pathway to the protein cationicity and
oligomer formation, discarding any correlation between the
RNase catalytic activity and the autophagic process (75). Two
main factors, protein net charge, and stability of the oligomers
were considered to explain the difference between RNaseA and
BS-RNase in inducing autophagy. Last but not least, there is
another human RNase, the RNase L, unrelated to the RNaseA
superfamily, which can also trigger the autophagy pathway.
RNase L expression is induced during viral infection. The
protein can initiate autophagy and suppress thereby the virus
replication (31, 76). In all cases, we can outline a convergent
mechanismwhere the RNases induction of autophagy is activated
by a cell stress condition: oxidative injury, presence of protein
aggregation, or infection (18, 77).
In summary, the present results have revealed the potentiality
of human secretory RNases to work as antimicrobial agents in
the fight against tuberculosis, extendable to other intracellular
infectious bacterial diseases that are difficult to eradicate (78).
AMPs that display a multifaceted mechanism of action (12,
16, 79–85), like human antimicrobial RNases, deserve a special
attention for their pharmacological potential. Our ongoing inter-
disciplinary investigation warrants the understanding of RNases’
antimicrobial mechanism of action and can pave the design of
novel anti-infective therapies.
CONCLUSIONS
Screening of the seven main human canonical members of the
RNaseA superfamily identified three RNases (RNase3, RNase6,
and RNase7) that achieved the eradication ofM. aurum infection
within macrophages at a low micromolar range. The protein
antimicrobial activity was found not dependent on the RNase
enzymatic activity. Out of the three antimycobacterial RNases,
two of them (RNase3 and RNase6) demonstrated their ability
to induce macrophage autophagy and thereby inhibit M. aurum
intracellular growth. The expression of both RNases in human
THP1 derived macrophage cells is regulated by the mycobacterial
infection, suggesting an in vivo physiological role.
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Figure S1 | A representative SPOTi image comparing human RNases activity on
M. aurum cultures. M. aurum was incubated with serially diluted recombinant
human RNases (ranging from 2 to 32µM) for 4 h in phosphate-buffered saline
(PBS). Next, an aliquot was spotted onto wells of a 24-well plate containing
MB7H10/OADC/agar and incubated at 37◦C for 4–5 days to determine survival.
Figure S2 | Confocal microscopy analysis of RAW 264.7 cell culture (2.5 × 105
cells/mL) incubated with 2µM of RNase3 labeled with Alexa Fluor 488. Cells were
stained with Hoechst and Deep Red following the assay incubation conditions
detailed in the experimental procedures section. After addition of Alexa Fluor 488
labeled protein (green), the evolution of the fluorescence signals was analyzed by
confocal microscopy. A total of 20 cells were analyzed by regions of interest (ROIs)
using Leica TCS software. The images were taken using a Leica TCS SP5
AOBS microscope.
Figure S3 | 3D reconstruction of RAW 264.7 macrophages post-treatment with
RNase3. Confocal microscopy analysis of RAW 264.7 cell culture incubated with
2µM of RNase3 labeled with Alexa Fluor 488 (green). Cells were stained with
Hoechst and Deep Red following the assay incubation conditions detailed in the
experimental procedures section. After 45min of protein addition, the
fluorescence signals of Hoechst and AlexaFluor (A) and Hoechst, AlexaFluor and
Deep Red (B) were analyzed by confocal microscopy. The images were taken
using a Leica TCS SP5 AOBS microscope.
Figure S4 | Confocal microscopy analysis of RAW 264.7 cell culture incubated
with human RNases labeled with Alexa Fluor 488. Cells were stained with Hoechst
and Deep Red following the assay incubation conditions detailed in the
experimental procedures section. After labeled protein addition (green), the
evolution of the fluorescence signals was analyzed by confocal microscopy for
30min. A total of 20 cells were analyzed by regions of interest (ROIs) using Leica
TCS software. The images were taken using a Leica TCS SP5 AOBS microscope.
Each panel indicates the RNase assayed.
Figure S5 | Expression pattern of human RNases in THP-1 derived macrophage
cells infected with M. aurum. Human THP-1 macrophage derived cells were
infected with M. aurum for 4, 24, 48, and 72 h. The transcriptional expression of
human RNase2, RNase3, RNase6, and RNase7 were detected by real-time qPCR
and all samples were normalized with the GAPDH housekeeping gene. (A) relative
expression of RNase2, RNase3, RNase6, and RNase7 at 0 h without infection;
(B–D) The monitoring of RNases’ expression upon infection was presented as the
fold change of relative expression in infected group compared with the
corresponding control group at each time point. Results are shown from 3
independent experiments (mean ± SD), ∗ indicates a significant difference
compared with control (p value < 0.05).
Figure S6 | Quantification of acidic vesicular compartment measured by AO
staining. The total amount of acidic vesicles was assessed as an estimate of
autolysosome formation. Mouse RAW 264.7 macrophage cells were treated with
RNases 3 and 7 for 24 h. Values are presented as means ± SD of 8 replicates.
∗ indicates significant difference compared with control group (p ≤ 0.05).
Figure S7 | Comparison of aggregation of DOPG/DOPC liposomes by RNases.
The incubation time of protein with liposomes is 30min for all assay. The proteins
were 2-fold serially diluted (from 1.6 to 0.05µM).
Figure S8 | RNase3 and RNase3-H15A antimycobacterial activity in the presence
of autophagy regulators. RAW 264.7 macrophages were infected with M. aurum
and treated with different concentration of the proteins, and/or 100 nM of
rapamycin (Rapa), and/or 100 nM of bafilomycin A (BA), and/or 5mM of 3
methyladenine (3MA) for 24 h in RPMI-1640 complete medium. Macrophages
were washed twice with RPMI-1640 and lysed, and then an aliquot was spotted
onto wells of a 24-well plate containing MB7H10/OADC/agar and incubated at
37◦C for 4–5 days to determine intracellular survival.
Figure S9 | Sequence alignment and prediction of aggregation propensity of eight
human RNases. (A) Alignment of the eight human canonical RNases using the
ESPript3 software (espript.ibcp.fr/), the N-terminal domain is highlighted in blue.
Sequence allocation was performed following the homology between RNases.
(B) 3D structure of RNases by Aggrescan3D (A3D). A3D exploits an
experimentally derived intrinsic aggregation propensity scale for natural amino
acids. This structure-based approach identifies aggregation patches (in red) at the
protein surface. (C) Aggregation profile propensity of RNase3, RNase6, and
RNase7 based on A3D score for protein residues.
Table S1 | Primer sequences for real-time qPCR. Primers of human GAPDH,
RNase2, RNase3, RNase6, and RNase7, and human and mouse β-actin,
Beclin-1, and ATG5.
Table S2 | Comparison of physicochemical parameters of human secretory
RNases. pI and Grand average of hydropathy (GRAVY) were predicted using the
ProtParam tool (https://web.expasy.org/translate/).
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